CREAR
Rosario, Argentina
Guillermo Pons-Estel obtained his medical degree from the Universidad Nacional de Rosario (UNR), completed his training in Medical Clinic at the Hospital Granadero Baigorria, UNR and obtained his degree in Rheumatology from the Colegio de Médicos de la 2da Circunscripción de Santa Fe, Argentina. He received the "STELLAR" scholarship to complete his fellowship in the Department of Medicine. Division of Clinical Immunology and Rheumatology, Schools of Medicine and Public Health, University of Alabama, Birmingham, Alabama, United States of America (2007-2008) Between 2008 and 2012, at the University of Barcelona (UB), he completed his Master's degree in Autoimmune Diseases and Doctor of Medicine, continuing his activity as "Post-doctoral Fellow" in the Department of Autoimmune Diseases at the Hospital Clinic, Barcelona, until 2017.
He is currently an assistant physician at the Regional Center of Autoimmune and Rheumatic Diseases (CREAR) in Rosario, Argentina and Director of the Research Unit of the Argentine Society of Rheumatology (UNISAR). He is also coordinator of the GLADEL 2.0 cohort and of the Antiphospholipid Syndrome Study Group (GESAF) of the Argentine Society of Rheumatology (SAR).
Saturday, November 16, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose
0639: Delayed Diagnosis in Systemic Lupus Erythematosus
Saturday, November 16, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose
Sunday, November 17, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose
Sunday, November 17, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose
1511: Lupus Nephritis and Response to Treatment in Latin America
Sunday, November 17, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose
Monday, November 18, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose
Monday, November 18, 2024
10:30 AM – 12:30 PM Eastern Time
No financial relationships with ineligible companies to disclose